Research map: Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research

Back to the article

Papers in this map

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  2. Building a Common Language for Cervical Cancer Clinical Trials · Letícia de Mello Graziano · 2026 · Cites this paper
  3. A step forward for precision oncology in thyroid cancer · 2026 · Related
  4. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology · N.K. Aaronson · 1993 · 16256 citations · Cited by this paper
  5. RCP calls for UK to recognise air pollution as a public health emergency · 2026 · Related
  6. Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer · Peter Graham Rose · 1999 · 2695 citations · Cited by this paper
  7. French MPs vote for sharp cuts in cadmium content in fertilisers · 2026 · Related
  8. Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix · William A. Peters · 2000 · 2339 citations · Cited by this paper
  9. The intermediate-risk gap in AI-based breast cancer stratification · 2026 · Related
  10. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology · Richard Pötter · 2006 · 1638 citations · Cited by this paper
  11. Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial · 2026 · Related
  12. ESHRE Guideline: management of women with premature ovarian insufficiency · The ESHRE Guideline Group on POI · 2016 · 1606 citations · Cited by this paper
  13. Gastric cancer with peritoneal metastases: hype or hope for HIPEC? · 2026 · Related
  14. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group☆ (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV · Christine Haie-Méder · 2005 · 1566 citations · Cited by this paper
  15. Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS) · 2026 · Related
  16. Improved Survival with Bevacizumab in Advanced Cervical Cancer · Krishnansu S. Tewari · 2014 · 1534 citations · Cited by this paper
  17. Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study · 2026 · Related
  18. Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) · Ethan Basch · 2014 · 1173 citations · Cited by this paper
  19. Radiotherapy dose escalation in glioblastoma: the thin ice of of historical controls · 2026 · Related
  20. Revised FIGO staging for carcinoma of the cervix uteri · Neerja Bhatla · 2019 · 1067 citations · Cited by this paper
  21. Small Cell and Other Rare Histologic Types of Cervical Cancer · 2022 · Related
  22. Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials · 2008 · 986 citations · Cited by this paper
  23. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study · Richard Pötter · 2021 · 673 citations · Cited by this paper
  24. Long-term health consequences of premature or early menopause and considerations for management · Stephanie S. Faubion · 2015 · 543 citations · Cited by this paper
  25. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* · David Cibula · 2023 · 484 citations · Cited by this paper
  26. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) · Andreas du Bois · 2005 · 470 citations · Cited by this paper
  27. Bilateral Negative Sentinel Nodes Accurately Predict Absence of Lymph Node Metastasis in Early Cervical Cancer: Results of the SENTICOL Study · Fabrice R Lecuru · 2011 · 469 citations · Cited by this paper
  28. Survival with Cemiplimab in Recurrent Cervical Cancer · Krishnansu S. Tewari · 2022 · 458 citations · Cited by this paper
  29. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial · Domenica Lorusso · 2024 · 399 citations · Cited by this paper
  30. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505 · Ryo Kitagawa · 2015 · 395 citations · Cited by this paper
  31. The European Organization for Research and Treatment of Cancer (EORTC) Quality‐of‐Life questionnaire cervical cancer module · Elfriede Greimel · 2006 · 325 citations · Cited by this paper
  32. Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer · Marie Plante · 2024 · 279 citations · Cited by this paper
  33. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826 · Bradley J. Monk · 2023 · 270 citations · Cited by this paper
  34. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer · Kathleen M. Schmeler · 2021 · 241 citations · Cited by this paper
  35. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial · Ana Oaknin · 2023 · 240 citations · Cited by this paper
  36. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial · Linda Mileshkin · 2023 · 204 citations · Cited by this paper
  37. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer · Ignace B. Vergote · 2024 · 193 citations · Cited by this paper
  38. SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study · Fabrice R Lecuru · 2019 · 190 citations · Cited by this paper
  39. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial · Mary McCormack · 2024 · 172 citations · Cited by this paper

Source: OpenAlex (CC0)